| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1658 | 2019 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 481 | 2021 |
| A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive … SH Park, DH Lim, TS Sohn, J Lee, DY Zang, ST Kim, JH Kang, SY Oh, ... Annals of Oncology 32 (3), 368-374, 2021 | 231 | 2021 |
| Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial J Lee, ST Kim, K Kim, H Lee, I Kozarewa, PGS Mortimer, JI Odegaard, ... Cancer discovery 9 (10), 1388-1405, 2019 | 188 | 2019 |
| Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN L Paz-Ares, Y Chen, N Reinmuth, K Hotta, D Trukhin, G Statsenko, ... ESMO open 7 (2), 100408, 2022 | 178 | 2022 |
| CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... Lancet 394 (10212), 1929-1939, 2019 | 133 | 2019 |
| Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer JH Ji, YL Oh, M Hong, JW Yun, HW Lee, DG Kim, Y Ji, DH Kim, WY Park, ... PLoS genetics 11 (8), e1005467, 2015 | 129 | 2015 |
| ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). SH Park, DY Zang, B Han, JH Ji, TG Kim, SY Oh, IG Hwang, JH Kim, ... Journal of Clinical Oncology 37 (15_suppl), 4001-4001, 2019 | 86 | 2019 |
| Durvalumab±tremelimumab+ platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. LG Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... Journal of Clinical Oncology 38 (15_suppl), 9002-9002, 2020 | 85 | 2020 |
| Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for … SH Moon, SH Cho, LC Park, JH Ji, JM Sun, JS Ahn, K Park, JY Choi, ... European journal of nuclear medicine and molecular imaging 40, 1005-1013, 2013 | 63 | 2013 |
| The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. S Park, SH Moon, LC Park, DW Hwang, JH Ji, CH Maeng, SH Cho, ... American journal of hematology 87 (9), 937-940, 2012 | 58 | 2012 |
| PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN L Paz-Ares, JW Goldman, MC Garassino, M Dvorkin, D Trukhin, ... Annals of Oncology 30, v928-v929, 2019 | 56 | 2019 |
| CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... Lancet Oncol 22 (1), 51-65, 2021 | 48 | 2021 |
| Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis JH Ji, SH Park, J Lee, TW Kim, YS Hong, K Kim, SY Kim, JY Baek, ... Cancer chemotherapy and pharmacology 72, 223-230, 2013 | 47 | 2013 |
| A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with … IG Hwang, JH Ji, JH Kang, HR Lee, HY Lee, KC Chi, SW Park, SJ Lee, ... Journal of geriatric oncology 8 (3), 170-175, 2017 | 46 | 2017 |
| Treatment of dexamethasone‐induced hiccup in chemotherapy patients by methylprednisolone rotation GW Lee, SY Oh, MH Kang, JH Kang, SH Park, IG Hwang, SY Yi, YJ Choi, ... The Oncologist 18 (11), 1229-1234, 2013 | 43 | 2013 |
| Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized … JW Goldman, MC Garassino, Y Chen, M Özgüroğlu, M Dvorkin, D Trukhin, ... Lung Cancer 149, 46-52, 2020 | 40 | 2020 |
| Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma YS Kim, IG Hwang, SE Park, SI Go, JH Kang, I Park, SY Oh, JH Ji, ... Cancer chemotherapy and pharmacology 77, 979-985, 2016 | 37 | 2016 |
| Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: The VIKTORY umbrella trial. Cancer Discov. 2019; 9: 1388–1405. doi: 10.1158/2159-8290 J Lee, ST Kim, K Kim, H Lee, I Kozarewa, PGS Mortimer, JI Odegaard, ... CD-19-0442.[Abstract][CrossRef][Google Scholar], 0 | 33 | |
| Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma EJ Kang, MJ Ahn, CY Ock, KW Lee, JH Kwon, Y Yang, YH Choi, MK Kim, ... Clinical Cancer Research 27 (19), 5272-5279, 2021 | 31 | 2021 |
Nikolay Vladimirov ConevMedical University of Varna在 mu-varna.bg 的电子邮件经过验证
